RACE Concussion Study: Rapid, accurate assessment of blood biomarkers for concussion

Summary

We are investigating if biosensor can accurately measure blood biomarkers of concussion. Concussion diagnoses and prognoses are currently reliant on subjective measures. A biosensor that can objectively measure concussion could supplement subjective measures. This would allow early diagnosis or recovery monitoring to reduce recovery times.

All participants in this study will complete initial visit measures upon enrolment. These include questionnaires (15 minutes) and a blood draw (5 minutes). Participants with concussion will return for follow-up visits at 2, 6, and 12 weeks after injury or until recovery. They will also complete a daily online symptom survey (2 minutes), and be given access to concussion education resources. Participants with a muscular or skeletal injury will only complete initial visit measures.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 65

Inclusion criteria:

1) Concussion OR muskuloskeletal injury (broken bone, pulled muscle, connective tissue damage, etc.) diagnosis within one week before first study visit.
2) Ages 18 through 65 years old

Exclusion criteria:

1) History of neurological diseases (stroke, seizures, epilepsy, dementia, etc.)
2) Current metabolic disease (liver disease, kidney disease, cardiovascular disease, diabetes, etc.)
3) A prior moderate or severe brain injury
4) Any secondary injury during the same time as the concussion or musculoskeletal injury

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Please contact Linden Penner (study coordinator) for more information.

Principal investigator:

Chantel Debert

Clinical trial:

No

REB-ID:

REB22-1015